Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05587205Phase 1Recruiting

Safety and Tolerability of EO2002

Role: collaborator

NCT05636579Phase 1Recruiting

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Role: collaborator

NCT04894110Phase 1Completed

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Role: lead

NCT04191629Phase 1Unknown

Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema

Role: collaborator

All 4 trials loaded